Pharmaceuticals news FT.com

EU regulator declines approval for Eli Lilly’s new Alzheimer’s drug

European Medicines Agency says risks of potentially fatal side effects from donanemab outweigh benefits

Mar 28, 2025 - 13:44
 0
EU regulator declines approval for Eli Lilly’s new Alzheimer’s drug
European Medicines Agency says risks of potentially fatal side effects from donanemab outweigh benefits
Read More

Tags:

Previous Article

Car buyers demand more information before committing to EVs, study finds

Next Article

Manufacturing issues trip up Milestone's long-awaited FDA landmark

Related Posts

China investigates generic drugs over safety concerns

China investigates generic drugs over safety concerns

Feb 9, 2025  0

The big haul

The big haul

Feb 9, 2025  0

Altman-backed Retro Biosciences to raise $1bn for project to extend human life

Altman-backed Retro Biosciences to raise $1bn for proje...

Feb 9, 2025  0